Brussels - Delayed Quote EUR

Hyloris Pharmaceuticals SA (HYL.BR)

Compare
6.08
0.00
(0.00%)
At close: January 10 at 4:53:27 PM GMT+1
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,087.00
2,087.00
900.00
3,096.00
175.00
Cost of Revenue
93.00
93.00
94.00
107.00
145.00
Gross Profit
1,994.00
1,994.00
806.00
2,989.00
30.00
Operating Expense
17,840.00
17,840.00
12,314.00
13,337.00
5,586.00
Operating Income
-15,846.00
-15,846.00
-11,508.00
-10,348.00
-5,556.00
Net Non Operating Interest Income Expense
769.00
769.00
-444.00
-550.00
-478.00
Pretax Income
-15,380.00
-15,380.00
-11,901.00
-11,282.00
-7,145.00
Tax Provision
--
--
4.00
297.00
1.00
Net Income Common Stockholders
-15,380.00
-15,380.00
-11,906.00
-11,579.00
-7,145.00
Diluted NI Available to Com Stockholders
-15,380.00
-15,380.00
-11,906.00
-11,579.00
-7,145.00
Basic EPS
-0.56
-0.56
-0.43
-0.45
-0.33
Diluted EPS
-0.56
-0.56
-0.43
-0.45
-0.33
Basic Average Shares
--
28,000.37
27,198.93
25,832.63
21,818.81
Diluted Average Shares
--
28,000.37
27,198.93
25,832.63
21,818.81
Total Operating Income as Reported
-15,993.00
-15,993.00
-11,638.00
-10,541.00
-7,025.00
Total Expenses
17,933.00
17,933.00
12,408.00
13,444.00
5,731.00
Net Income from Continuing & Discontinued Operation
-15,380.00
-15,380.00
-11,906.00
-11,579.00
-7,145.00
Normalized Income
-15,236.00
-15,236.00
-12,135.50
-11,579.00
-7,202.51
Interest Income
869.00
869.00
67.00
32.00
543.00
Interest Expense
52.00
52.00
219.00
556.00
992.00
Net Interest Income
769.00
769.00
-444.00
-550.00
-478.00
EBIT
-15,328.00
-15,328.00
-11,682.00
-10,726.00
-6,153.00
EBITDA
-14,980.00
-14,980.00
-11,486.00
-10,612.00
-5,572.00
Reconciled Cost of Revenue
93.00
93.00
94.00
107.00
145.00
Reconciled Depreciation
348.00
348.00
196.00
114.00
581.00
Net Income from Continuing Operation Net Minority Interest
-15,380.00
-15,380.00
-11,906.00
-11,579.00
-7,145.00
Total Unusual Items Excluding Goodwill
-144.00
-144.00
306.00
--
81.00
Total Unusual Items
-144.00
-144.00
306.00
--
81.00
Normalized EBITDA
-14,836.00
-14,836.00
-11,792.00
-10,612.00
-5,653.00
Tax Rate for Calcs
--
--
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
76.50
--
23.49
12/31/2020 - 6/29/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

OXUR.BR Oxurion NV
0.2355
-1.05%
 
BIOS.BR BioSenic S.A.
0.0058
-4.92%
 
ARGX.BR argenx SE
644.00
+0.25%
 
TUB.BR Financière de Tubize SA
151.40
-0.13%
 
41O.MU Outlook Therapeutics Inc
2.1600
0.00%
 
PHGN.F Pharming Group N.V.
0.9180
-0.76%
 
ONWD.BR Onward Medical N.V.
6.36
+6.00%
 
IVA.PA Inventiva S.A.
2.1400
0.00%
 
63E.SG Onward Medical N.V.
6.32
+17.04%
 
CHGX.CN ChitogenX Inc.
0.0250
+66.67%